# US 2024/0197722 A1 · Anticancer composition inducing cell senescence and cell death

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197722 A1
- Document ID: US20240197722A1
- Status: Published application
- Kind: A1
- Application number: 18/553,311
- Filed: 2022-04-14
- Published: 2024-06-20
- Earliest claimed: 2021-04-20
- Assignees: Osteoneurogen Inc.
- Applicants: Osteoneurogen Inc.
- Inventors: Byung Soo YOUN; Moon Kee MEANG; Saes Byeol KIM; Ik Hwan KIM; Han Soo KIM
- Web page: https://patentgrep.com/patent/US20240197722A1

## CPC

- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an anticancer composition containing as an active ingredient a compound inducing cell senescence and apoptosis. The compound of the present invention can discriminate cancer cells and normal cells and induce both cell senescence and apoptosis in a cancer cell-specific manner. Thus, the compound does not need the attachment of any cancer cell-specific targeting substance thereto, can minimize the frequent adverse effects caused by the attack of anticancer agents on normal cells, and exhibits a potent anticancer effect on the basis of the aforementioned dual action.

## Claims

### Claim 1

A method for inhibiting or treating or ameliorating tumor or cancer disease in a subject in need thereof, comprising:
administering an effective amount of a compound represented by Chemical Formula 1 below or a salt thereof as an active ingredient to a subject in need thereof:
wherein in Chemical Formula 1 above,
R1 is a C1-5 alkyl, a C5-6 cyclic alkyl, a C5-6 cyclic alkyl containing at least one heteroatom of O or N, a C6-12 aryl or a C5-6 heteroaryl containing at least one heteroatom of O or N,
wherein R2 is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy,
wherein R3 is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy,
wherein R4 is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy, and
wherein R5 is hydrogen, hydroxy, methyl, methoxy, acetoxy, carboxy or benzoyloxy.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 is methyl, ethyl, cyclopentyl, cyclohexyl or phenyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein R1 is methyl,
wherein R2 is hydrogen,
wherein R3 is hydrogen, hydroxy or methoxy,
wherein R4 is hydroxy or methoxy, and
wherein R5 is hydrogen, hydroxy or methoxy.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is represented by any one of Chemical Formulas 2 to 5 below:

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is blood cancer or solid cancer.

### Claim 6 (depends on 5)

The method of claim 5, wherein the blood cancer is leukemia, malignant lymphoma, multiple myeloma or aplastic anemia.

### Claim 7 (depends on 5)

The method of claim 5, wherein the solid cancer is brain tumor, benign astrocytoma, malignant astrocytoma, pituitary adenoma, meningioma, brain lymphoma, oligodendroglioma, craniopharyngioma, ependymoma, brainstem tumor, head and neck tumor, laryngeal cancer, oropharyngeal cancer, nasal cancer, nasopharyngeal cancer, salivary gland cancer, hypopharyngeal cancer, thyroid cancer, oral cancer, chest tumor, small cell lung cancer, non-small cell lung cancer, thymus cancer, mediastinal tumor, esophageal cancer, breast cancer, male breast cancer, abdominal tumor, stomach cancer, liver cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, small intestine cancer, colon cancer, anal cancer, bladder cancer, kidney cancer, male genital tumor, penile cancer, prostate cancer, female genital tumor, cervical cancer, endometrial cancer, ovarian cancer, uterine sarcoma, vaginal cancer, female external genital cancer, female urethral cancer or skin cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound exhibits antitumor or anticancer activity by at least one action selected from the group consisting of:
(i) inhibition of tumor or cancer cell-specific proliferation by the induction of replicative senescence (RS) and/or oncogene-induced senescence (OIS);
(ii) reversal of the tumor or cancer cell NAD/NADH ratio;
(iii) upregulation of tumor or cancer cell ROS; and
(iv) inducing tumor or cancer cell-specific apoptosis.

### Claim at position 9

9-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the compound or a salt thereof is administered as a pharmaceutical composition, a quasi drug composition or a food composition.
